Press Releases

Showing 71-105 of 252

First Prev 1 2 3 4 5 6 7 8 Next Last

2012
June
June 27	Abbott, The Abbott Fund and Direct Relief International Reach Key HIV Testing Milestones: 20 Million Tests Provided Over 10 Years, and More Than 150,000 HIV Cases Prevented in Children
June 26	Abbott Introduces New Limited Ingredient Nutrition Bar – Perfectly Simple™ by ZonePerfect®
June 25	Abbott Receives Positive Opinion for HUMIRA® in Non-radiographic Axial Spondyloarthritis from EMA's CHMP
June 20	Abbott Again Named One of the Best Workplaces in Europe
June 18	Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinson's Disease
June 12	Abbott Expands CFChef Program in 2012 for People Affected by Cystic Fibrosis
June 8	Abbott Declares 354th Consecutive Quarterly Dividend
June 6	Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
June 6	Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
June 6	Abbott Announces 10-Year Data Evaluating HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis
June 5	Abbott Introduces Ensure Clear™ to Help Adults Fill Dietary Gap
June 5	Abbott Announces Initiation of Phase 3 Study of Elagolix in Patients with Endometriosis
June 1	Abbott Again Recognized as One of the 'Best Places to Work in Industry' by The Scientist Magazine

May
May 29	Abbott to Present at Goldman Sachs 33rd Annual Global Healthcare Conference
May 29	Abbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA® (Adalimumab) at the Annual Meeting of the European League Against Rheumatism - (Europe)
May 29	Abbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA® (Adalimumab) at the Annual Meeting of the European League Against Rheumatism - (U.S.)
May 16	Abbott Launches PediaSure SideKicks® Clear for Picky Eaters
May 15	Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
May 7	Abbott Reaches Settlement Agreement on Depakote
May 4	Abbott Recognizes Winners of Supplier Excellence Award
May 3	Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
May 3	Abbott to Acquire Action Pharma's Investigational Compound, AP214, in Phase 2b Development for Prevention of Acute Kidney Injury
May 2	Abbott to Present at Deutsche Bank 37th Annual Health Care Conference

April
April 25	New Products from Abbott’s EAS® Sports Nutrition Brand Help Athletes Improve Post-Workout Recovery and Meet Fitness Goals
April 23	Abbott and St. Jude Medical Broaden Alliance for Cardiovascular Products in the United States
April 20	Abbott Receives U.S. FDA Clearance to Use iFS Advanced Femtosecond Laser Technology for Arcuate Incisions in Cataract Surgery
April 19	Abbott Presents Positive Results from Phase 2 "Pilot" Study of an Interferon-Free Combination Regimen for the Treatment of Hepatitis C
April 19	Abbott Presents Positive Results from Interferon-Free Phase 2 "Co-Pilot" Study for the Treatment of Hepatitis C
April 18	Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter; Raises Full-Year 2012 Outlook
April 17	Abbott Licenses Biomarkers for Use in Differentiating Aggressive from Nonaggressive Prostate Cancer
April 17	Abbott’s Investigational Treatment for Advanced Parkinson’s Disease Demonstrates Positive Results in Phase 3 Clinical Trial
April 11	Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)
April 9	Abbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent in Japan
April 4	Abbott to Present Positive Phase 2 Results from Multiple Interferon-Free Studies of Combination Regimens for the Treatment of Hepatitis C

March
March 30	Abbott's PLEX-ID Molecular System and Tests for Broad Microbial Identification Obtain CE Marking

First Prev 1 2 3 4 5 6 7 8 Next Last

Narrow by Year

Narrow to Show

For a different perspective on Abbott News. . .

View Abbott Feature Stories

© 2006, 2013 Abbott Laboratories, Abbott Park, Illinois, USA

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.